A listing of human tumor antigens recognized by T cells: March 2004 update
L Novellino, C Castelli, G Parmiani - Cancer Immunology, Immunotherapy, 2005 - Springer
The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …
the number of tumor associated antigens (TAA) that are currently available for clinical …
Epitope-based vaccines: an update on epitope identification, vaccine design and delivery
A Sette, J Fikes - Current opinion in immunology, 2003 - Elsevier
The basic premise of the epitope-based approach to vaccine development is that, in certain
cases, the responses induced by the natural immunogen are not optimal, and can be …
cases, the responses induced by the natural immunogen are not optimal, and can be …
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas
J Dengjel, MD Nastke, C Gouttefangeas… - Clinical cancer …, 2006 - AACR
Purpose: To elicit a long-lasting antitumor immune response, CD8+ and CD4+ T cells
should be activated. We attempted to isolate HLA-DR–presented peptides directly from …
should be activated. We attempted to isolate HLA-DR–presented peptides directly from …
Phase I Trial of Intratumoral Injection of CCL21 Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration
JM Lee, MH Lee, E Garon, JW Goldman… - Clinical Cancer …, 2017 - AACR
Purpose: A phase I study was conducted to determine safety, clinical efficacy, and antitumor
immune responses in patients with advanced non–small cell lung carcinoma (NSCLC) …
immune responses in patients with advanced non–small cell lung carcinoma (NSCLC) …
Personalized immunotherapy against several neuronal and brain tumors
S Kuttruff-coqui, T Weinschenk, J Fritsche… - US Patent …, 2021 - Google Patents
2014-11-12 Assigned to IMMATICS BIOTECHNOLOGIES GMBH reassignment IMMATICS
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
BIOTECHNOLOGIES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT …
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer
G Betts, E Jones, S Junaid, T El-Shanawany, M Scurr… - Gut, 2012 - gut.bmj.com
Background There is indirect evidence that T cell responses can control the metastatic
spread of colorectal cancer (CRC). However, an enrichment of CD4+ Foxp3+ regulatory T …
spread of colorectal cancer (CRC). However, an enrichment of CD4+ Foxp3+ regulatory T …
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma
JL Gulley, PM Arlen, KY Tsang, J Yokokawa… - Clinical Cancer …, 2008 - AACR
Purpose: Poxviral vectors have a proven safety record and can be used to incorporate
multiple transgenes. Prior clinical trials with poxviral vaccines have shown that immunologic …
multiple transgenes. Prior clinical trials with poxviral vaccines have shown that immunologic …
Immunotherapy against neuronal and brain tumors
T Weinschenk, O Schoor, C Trautwein, N Hilf… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the …
immunotherapeutic methods. In particular, the present invention relates to the …
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients
E Tassi, F Gavazzi, L Albarello, V Senyukov… - The Journal of …, 2008 - journals.aai.org
Pancreatic carcinoma is a very aggressive disease with dismal prognosis. Although
evidences for tumor-specific T cell immunity exist, factors related to tumor microenvironment …
evidences for tumor-specific T cell immunity exist, factors related to tumor microenvironment …
Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with …
Y Ueda, T Itoh, I Nukaya… - International …, 2004 - spandidos-publications.com
We conducted a clinical study of cancer vaccine therapy with dendritic cells (DCs) and HLA-
A24-restricted carcinoembryonic antigen (CEA)-derived peptide to assess the feasibility and …
A24-restricted carcinoembryonic antigen (CEA)-derived peptide to assess the feasibility and …